VIRIDIAN THERAPEUTICS INC

Viridian Therapeutics insider buying signals confidence: Chief Legal Officer sells and buys shares to balance liquidity and long‑term stake, reflecting bullish outlook.

Viridian Therapeutics insider buying at $13.21 a share shows strong confidence in its TED pipeline, signaling upside potential for investors and partners.

Viridian insiders buy 32,341 shares post FDA approval for its TED therapy—signaling confidence, lock‑up stability, and a bullish outlook for the company’s orphan drug pipeline.

Fairmount’s $17.00 buy of 1.18 M Viridian shares signals institutional confidence that the $342 M capital raise will fuel safe, efficacious Phase 3 trials for the company’s promising TED therapy, VT‑101, and help secure a breakthrough‑therapy design…